On July 2, 2020, Alexion completed its acquisition of Portola through the merger of Buyer with and into Portola without a vote of Portola’s shareholders pursuant to Section 251 (h) of the Delaware General Corporation Law. By leveraging Alexion’s strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders.”, “In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. © 2021, Nasdaq, Inc. All Rights Reserved. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Stock Symbol: PTLA Company Name - Buyer: Alexion Pharmaceuticals, Inc. Stock Symbol - Buyer: ALXN Status: Filed Merger Announcement Date: 3/5/2020 Filing Date: 6/10/2020 The Boston-based biotech giant will pay $18 per share for Portola, which was trading at $7.76 per share when markets closed Monday. [CDATA[/* >*/. Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops and commercializes drugs. As a result of the merger, Portola became a wholly owned subsidiary of … The merger agreement has been unanimously approved by the boards of Alexion and Portola. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Chiliz (CHZ) Coin: What Does the NFT Craze Mean for Chiliz Price Predictions? Media Forward-looking statements include, among other things, statements related to the proposed acquisition of Portola by Alexion, including: that the acquisition would add near-term diversification to Alexion’s commercial portfolio; that the acquisition provides the opportunity to apply Alexion’s demonstrated global commercial excellence to create long-term value for patients and shareholders; Alexion’s belief that Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban; that Alexion is well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders; that Alexion can drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting; and the expectation that the transaction will close in the third quarter of 2020. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care,” said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. */ On July 2, 2020, Alexion completed its acquisition of Portola through the merger of Buyer with and into Portola without a vote of Portola’s shareholders pursuant to Section 251(h) of the Delaware General Corporation Law. Portola closed Monday at $7.76 per share. On July 2, 2020, Alexion completed its acquisition of Portola through the merger of Buyer with and into Portola without a vote of Portola’s shareholders pursuant to Section 251(h) of the Delaware General Corporation Law. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. The Top 25 Cryptocurrencies to Know in 2021: BTC, ETH, XRP, XLM and More, Christie's $69M NFT Sale 'Like Nothing I Have Ever Seen,' Says Art Auction Specialist, U.S. As a SUBJECT: PORTOLA PHARMACEUTICALS, INC. – TENDER OFFER OPTION SYMBOLS: PTLA DATE: 7/1/20 Portola Pharmaceuticals, Inc. (PTLA) is the subject of an Offer to Purchase (The “Offer”), as described below: PURCHASER: Odyssey Merger Sub Inc., a wholly owned subsidiary of Alexion Pharmaceuticals, Inc. SECURITY TO BE BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a definitive merger agreement for Alexion to acquire Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Alexion Pharmaceuticals (NASDAQ: ALXN) is a more than $20 billion company that has announced it is acquiring Portola Pharmaceuticals (NASDAQ: PTLA) for … Alexion: On July 2, 2020, Alexion completed its acquisition of Portola through the merger of Buyer with and into Portola without a vote of Portola’s shareholders pursuant to Section 251(h) of the Delaware General Corporation Law. A replay of the call will be available for a limited period of time following the call. On July 2, 2020, Alexion completed its acquisition of Portola through the merger of Buyer with and into Portola without a vote of Portola’s shareholders pursuant to …
Ferrari Maske Vettel Kaufen, Kempa Hose Lang, Wie Viele Mastrinder Gibt Es In österreich, 24 Stunden-blutdruckmessung Ablauf, Tönnies Aktie Wert, Fisher-price Auto Rock 'n Play Sleeper Recall, Lockdown Schleswig-holstein Friseur, Omron Connect Email, Mt Melsungen Transfer, Uloric Side Effects,
Neue Kommentare